Please login to the form below

Not currently logged in
Email:
Password:
Rare diseases

Companies developing rare disease treatments face several unique challenges when it comes to regulatory and reimbursement submissions.

The most pressing of these include the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs) as well as the challenges associated with collecting appropriate evidence in rare diseases. Alongside this is determining the needs for HTA and payer bodies to ensure a positive value assessment and reimbursement.

As well as these challenges, there are fundamental issues for clinical trial design that are magnified in rare diseases such as determining appropriate sample sizes and comparators and generating evidence to support selected endpoints.

On 22 March this PMLiVE webinar, in association with Adelphi Values, will use real-world examples to highlight the importance of evidence such as appropriate endpoints, including COAs, and comparators in rare diseases to support regulatory and reimbursement submissions. 

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics